CME: New Perspectives on Biologic Therapy in Moderate to Severe Ulcerative Colitis

New Perspectives on Biologic Therapy in Moderate to Severe Ulcerative Colitis

New Perspectives on Biologic Therapy in Moderate to Severe Ulcerative Colitis

Should biological therapies and small molecular DMARDs be utilized earlier in treating patients with ulcerative colitis?

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This article discusses real-world data that supports the use of biological therapies and small molecule disease-modifying antirheumatic drugs (DMARDs) earlier in the treatment paradigm for ulcerative colitis.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.


    David T. Rubin, MD
    Professor of Medicine
    University of Chicago Medicine
    Chicago, IL

    Dr. Rubin has disclosed he receives consulting fees from AbbVie, Abgenomics, Allergan, Inc., Biomica, Boehringer Ingelheim, Ltd., Bristol-Myers Squibb, Celgene Corp./Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Glenmark Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceuticals, Lilly, Mahana Therapeutics, Medtronic, Narrow River Mgmt, Pfizer, Prometheus Laboratories, Reistone, Seres Therapeutics, Shire, Takeda, and Target PharmaSolutions, Inc. and he receives grant support from AbbVie, Genentech/Roche, Janssen Pharmaceuticals, Prometheus Laboratories, Shire, and Takeda. He is co-founder of GoDuRn, LLC.

    Reviewers/Content Planners/Authors:
    • Sean T. Barrett has nothing to disclose 
    • Nick Lombardi has ownership interest with Vertex Pharmacueticals
    • Barry A. Fiedel, PhD has nothing to disclose
    • Ashley Pluta has nothing to disclose
    • Brian P. McDonough, MD, FAAFP has nothing to disclose

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Translate emerging and real-world data on comparative efficacy and safety of anti-integrins and anti-TNFs to treatment planning
    • Understand the disease activity index and prognosis as an independent factor in determining treatment
  • Target Audience

    This activity is designed to meet the educational needs of gastroenterology physicians, nurses, nurse practitioners, and physician assistants.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Takeda.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free